ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Merus NV

Merus NV (2GH)

42.20
0.80
(1.93%)
Closed 09 December 8:00AM
Realtime Data

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
42.20
Bid
41.80
Offer
42.80
Volume
0.00
0.00 Day's Range 0.00
21.40 52 Week Range 58.50
Previous Close
41.40
Open
-
Last Trade
Last Trade Time
Average Volume (3m)
127
Financial Volume
-
VWAP
-

2GH Latest News

Zwischenergebnisse der Monotherapie mit Petosemtamab von Merus zeigen weiterhin klinisch signifikante Aktivität bei 2L+ r/m HNSCC

Zwischenergebnisse der Monotherapie mit Petosemtamab von Merus zeigen weiterhin klinisch signifikante Aktivität bei 2L+ r/m HNSCC Studie mit Petosemtamab in Kombination mit Pembrolizumab bei 1L...

Les données intermédiaires de Merus portant sur le pétosemtamab continuent de démontrer une activité cliniquement significative dans le traitement de 2e ligne et lignes ultérieures du CETC r/m

Les données intermédiaires de Merus portant sur le pétosemtamab continuent de démontrer une activité cliniquement significative dans le traitement de 2e ligne et lignes ultérieures du CETC r/m...

Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC

Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC Petosemtamab in combination with pembrolizumab in 1L r/m PD-L1 expressing...

Merus annonce l’autorisation par la FDA de BIZENGRI® (zénocutuzumab-zbco) dans le traitement de l’adénocarcinome pancréatique NRG1+ et du cancer du poumon non à petites cellules (CPNPC) NRG1+, en fonction des données de sécurité et d’efficaci

Merus annonce l’autorisation par la FDA de BIZENGRI® (zénocutuzumab-zbco) dans le traitement de l’adénocarcinome pancréatique NRG1+ et du cancer du poumon non à petites cellules (CPNPC) NRG1+, en...

Merus gibt FDA-Zulassung von BIZENGRI® (Zenocutuzumab-zbco) für NRG1+-Adenokarzinome der Bauchspeicheldrüse und NRG1+-nicht-kleinzelligen Lungenkrebs (NSCLC) auf der Grundlage von Sicherheits- und Wirksamkeitsdaten aus der eNRGy-Studie bekannt

Merus gibt FDA-Zulassung von BIZENGRI® (Zenocutuzumab-zbco) für NRG1+-Adenokarzinome der Bauchspeicheldrüse und NRG1+-nicht-kleinzelligen Lungenkrebs (NSCLC) auf der Grundlage von Sicherheits- und...

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy...

Merus und Partner Therapeutics geben Lizenzvereinbarung für die Vermarktung von Zenocutuzumab in den USA bei NRG1-fusionspositivem Krebs bekannt

Merus und Partner Therapeutics geben Lizenzvereinbarung für die Vermarktung von Zenocutuzumab in den USA bei NRG1-fusionspositivem Krebs bekannt UTRECHT, Niederlande, und CAMBRIDGE, Massachusetts...

Merus et Partner Therapeutics annoncent un contrat de licence en vue de la commercialisation aux États-Unis du zenocutuzumab dans le cadre du traitement des cancers à fusion NRG1 positive

Merus et Partner Therapeutics annoncent un contrat de licence en vue de la commercialisation aux États-Unis du zenocutuzumab dans le cadre du traitement des cancers à fusion NRG1 positive UTRECHT...

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 02...

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024 – Petosemtamab 1500 mg monotherapy phase 2 interim data continues to...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-1-2.3148148148143.2474319244.19451697DE
4-7.8-15.65051.540.411744.74603537DE
12-3-6.6371681415945.251.540.412747.17167127DE
26-6-12.448132780148.257.540.415948.57608533DE
5219.283.47826086962358.521.39999917344.34418355DE
15618.477.310924369723.858.51916742.00023485DE
26018.477.310924369723.858.51916742.00023485DE

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
TE9Teco 2030 ASA
0.0592 €
(65.36%)
2.11M
A6NAsana Inc
21.00 €
(43.84%)
19.08k
NL8Genesis Ai Corp
0.0214 €
(40.79%)
13.33k
RQ0DWave Quantum Inc
4.814 €
(34.92%)
1.15M
K8DWellfield Technologies Inc
0.0342 €
(34.65%)
30.8k
AXIAtos SE
0.0028 €
(-98.58%)
1.59B
M0YNMynaric AG
1.40 €
(-72.66%)
303.13k
W47Grid Battery Metals Inc
0.0115 €
(-39.47%)
7
47GAGo Metals Corp
0.0202 €
(-36.88%)
3.44k
4APApollo Minerals Ltd
0.0055 €
(-35.29%)
270.7k
AXIAtos SE
0.0028 €
(-98.58%)
1.59B
D7GNel ASA
0.2625 €
(-1.69%)
4.24M
LK1Lake Resources
0.029 €
(-6.75%)
2.32M
TUI1Tui AG
8.40 €
(1.11%)
2.17M
TE9Teco 2030 ASA
0.0592 €
(65.36%)
2.11M

Discussion

View Full Feed
Pickme2 Pickme2 3 minutes ago
You're right... I don't think anybody could find bigger set up to lose their money quicker from any other OTC ...You sure can find them!
Registration of 12,400,000 about to hit...along with public offering a 30 million....

Don't be ConDoged by the 🤡
ATMH
MrSteven MrSteven 8 minutes ago
Do you really think I am expecting any answer from you? The one who left organisation in september and is not entitled or not in a position to answer anything? And I do not expect company to answer me so better you don't care about myself attitude as I have seen your attitude and approach when you r
ITUP
mrfence mrfence 14 minutes ago
If the FHFA Director Nomination is "The one I want", that's precisely what's going to happen all month long.
FNMA
KILLAZILLA KILLAZILLA 17 minutes ago
Some just can't help themselves but to act like a complete imbecile...
WDLF
Flexplate Flexplate 19 minutes ago
I could only imagine what would happen with NBRI if they land a partnership with RGI. The sky is the limit.
NBRI
Fdc4 Fdc4 20 minutes ago
You know exactly what I meant, also you speak for yourself only because 90% of shareholders in here are screwed under-water AND that mate, is a FACT not gibberish like the one you tried to bring on. LMAOOOO
IGPK
The Whale The Whale 21 minutes ago
You're never getting your money back. NEVER!!!
GVSI
elijah17 elijah17 22 minutes ago
You guys think Dilution here at 2.50 ?
XRPUSD
Fdc4 Fdc4 22 minutes ago
If this opens over $0.0045, it will dump faster than a fart in the ponderosa…. Hahahahahahaha, not news, not FINRA or Audits, gosh, the closer this gets to DT getting on the chair in January, the worst is going to get for this Chinese PPS. Best thing Pumpers can do is to ignore, maybe pain ease a bi
IGPK
The Whale The Whale 23 minutes ago
I'm going to burn this pump and dump to the ground tomorrow. Nothing is happening until next summer.


BUYER BEWARE ☠☠☠

SCAM

$GVSI
GVSI
the_hoard the_hoard 28 minutes ago
Does anyone have status updates on the tax case with Immune Ltd in Israel?
TightCoil TightCoil 29 minutes ago
Tomorrow we obliterate the door of
resistance; we shall destroy that wall of oppression and corruption and deceit.
----Break Out and Break Through----
FNMA
Tesla Trillionaire Tesla Trillionaire 30 minutes ago
We have crossed into 400s and new ATHs again!!!! Tesla has risen!!! Investors have awoken!!!! DOGE!!!!!
TSLA
FlyFishingStocks FlyFishingStocks 32 minutes ago
https://www.zerohedge.com/markets/rfk-jr-effect-rotation-out-healthcare-stocks-shows-no-signs-abating RFK Jr. Effect: "Rotation Out Of Healthcare Stocks Shows No Signs Of Abating"

This follows what the XBI chart was projecting. Bios have been pinned down under overhead resistance f
AMRN XBI
MrSteven MrSteven 33 minutes ago
With all due respect my comments are nothing personal to you RD better you stop interrupting me and stop speaking on behalf of Laxmi and company. Unless you have an official letter of spokesperson on behalf of Laxmi and company. I can have much better attitude for you but I choose not to engage in
ITUP
Tadaaa Tadaaa 35 minutes ago
I thought he did quite well walking through the 60 Minutes Bastian of hell !

Represented the Crypto market in a Good Way
XRPUSD
fireballka7 fireballka7 35 minutes ago
BioA was a pink sheet company at that time. no need to report a thing. Next....
TexasMarvL TexasMarvL 36 minutes ago
Maybe it is just wishful thinking on my part that  Keith was in the audience for this 15 minute meeting.  It seems important that Keith was there and was mentioned. 

I can't imagine Keith has attended all of these investor conferences in the past.

It seems obvious the F
FFMGF
mrfence mrfence 42 minutes ago
At $12 dollars per share annual net profit, the intrinsic value of a share with a standard PE ratio of 10 to 30 would generate a PPS from $120 to $360 PPS depending on market sentiment.
FNMA
Stock Guy777 Stock Guy777 43 minutes ago
We can only hope!
TGGI
Stock Guy777 Stock Guy777 44 minutes ago
Microsoft's plan to win the console war: Make everything an Xbox
MSFT
rocketeer357 rocketeer357 45 minutes ago
No revenge signing of the polar bear?
rocketeer357 rocketeer357 46 minutes ago
Let's see how it plays out.
Maybe 2032 would be an apt time to count up the rings in Flushing and see how you're feeling about King Juan 

 As I recall, you were also quite euphoric when the Mets picked up Scherzer. And Verlander. And signed Correa for $350 million.
rocketeer357 rocketeer357 49 minutes ago
Wish El Tiante had gotten through, but very happy the Committee kept the door slammed on Senator Garvey.
The Night Stalker The Night Stalker 49 minutes ago
on sale
OMEX

Your Recent History

Delayed Upgrade Clock